[{"address1": "545 Concord Avenue", "address2": "Suite 210", "city": "Cambridge", "state": "MA", "zip": "02138", "country": "United States", "phone": "857 702 9600", "website": "https://www.metaviatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. MetaVia Inc.  operates as a subsidiary of Dong-A ST Co., Ltd.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Mr. Heon Kim  Hyung", "age": 48, "title": "CEO, President & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 716404, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marshall H. Woodworth", "age": 66, "title": "Chief Financial Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 565684, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mi-Kyung  Kim", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Homolka", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. W. Christopher Fang M.D.", "title": "Consulting Chief Medical Officer & Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael C. Pine", "age": 48, "title": "Senior Vice President of Business Development Advisor", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.85, "open": 1.02, "dayLow": 0.82, "dayHigh": 1.06, "regularMarketPreviousClose": 0.85, "regularMarketOpen": 1.02, "regularMarketDayLow": 0.82, "regularMarketDayHigh": 1.06, "payoutRatio": 0.0, "beta": 0.273, "volume": 42891198, "regularMarketVolume": 42891198, "averageVolume": 1984123, "averageVolume10days": 2144080, "averageDailyVolume10Day": 2144080, "bid": 0.9903, "ask": 0.829, "bidSize": 2, "askSize": 2, "marketCap": 21976450, "fiftyTwoWeekLow": 0.556, "fiftyTwoWeekHigh": 2.95, "allTimeHigh": 129540.0, "allTimeLow": 0.556, "fiftyDayAverage": 0.9467, "twoHundredDayAverage": 1.0186, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3075137, "profitMargins": 0.0, "floatShares": 7962773, "sharesOutstanding": 24197809, "sharesShort": 20160, "sharesShortPriorMonth": 99727, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0008, "heldPercentInsiders": 0.62511003, "heldPercentInstitutions": 0.0639, "shortRatio": 0.0, "shortPercentOfFloat": 0.0022, "impliedSharesOutstanding": 24197809, "bookValue": 0.261, "priceToBook": 3.4796934, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -18491000, "trailingEps": -0.97, "lastSplitFactor": "1:8", "lastSplitDate": 1703116800, "enterpriseToEbitda": -0.154, "52WeekChange": -0.6816479, "SandP52WeekChange": 0.1198014, "quoteType": "EQUITY", "currentPrice": 0.9082, "targetHighPrice": 21.0, "targetLowPrice": 3.0, "targetMeanPrice": 13.75, "targetMedianPrice": 15.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 17591000, "totalCashPerShare": 0.727, "ebitda": -20012000, "totalDebt": 98000, "quickRatio": 1.994, "currentRatio": 2.077, "debtToEquity": 1.018, "returnOnAssets": -0.53037, "returnOnEquity": -1.29462, "freeCashflow": -13114375, "operatingCashflow": -18903000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MTVA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1470403800000, "postMarketChangePercent": -13.532262, "postMarketPrice": 0.7853, "postMarketChange": -0.12290001, "regularMarketChange": 0.0582, "regularMarketDayRange": "0.82 - 1.06", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1984123, "fiftyTwoWeekLowChange": 0.35220003, "fiftyTwoWeekLowChangePercent": 0.6334533, "fiftyTwoWeekRange": "0.556 - 2.95", "fiftyTwoWeekHighChange": -2.0418, "fiftyTwoWeekHighChangePercent": -0.6921356, "fiftyTwoWeekChangePercent": -68.16479, "dividendDate": 1577750400, "earningsTimestampStart": 1755001800, "earningsTimestampEnd": 1755520200, "isEarningsDateEstimate": true, "exchange": "NCM", "messageBoardId": "finmb_630763379", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "MetaVia Inc.", "longName": "MetaVia Inc.", "corporateActions": [], "postMarketTime": 1762563543, "regularMarketTime": 1762549202, "regularMarketChangePercent": 6.84706, "regularMarketPrice": 0.9082, "marketState": "CLOSED", "epsTrailingTwelveMonths": -0.97, "fiftyDayAverageChange": -0.03849995, "fiftyDayAverageChangePercent": -0.04066753, "twoHundredDayAverageChange": -0.11039996, "twoHundredDayAverageChangePercent": -0.10838402, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "NeuroBo Pharmaceuticals, Inc.", "nameChangeDate": "2025-11-07", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "displayName": "MetaVia", "trailingPegRatio": null, "__fetch_time": "2025-11-08"}]